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Abstract: Cell therapy has been evaluated to enhance heart function after injury. Delivered cells
mostly act via paracrine mechanisms, including secreted growth factors, cytokines, and vesicles,
such as exosomes (Exo). Intramyocardial injection of cardiac-resident progenitor cells (CPC)-derived
Exo reduced scarring and improved cardiac function after myocardial infarction in rats. Here, we
explore a clinically relevant approach to enhance the homing process to cardiomyocytes (CM), which
is crucial for therapeutic efficacy upon systemic delivery of Exo. By overexpressing exosomal CXCR4,
we increased the efficacy of plasmatic injection of cardioprotective Exo-CPC by increasing their
bioavailability to ischemic hearts. Intravenous injection of ExoCXCR4 significantly reduced infarct size
and improved left ventricle ejection fraction at 4 weeks compared to ExoCTRL (p < 0.01). Hemodynamic
measurements showed that ExoCXCR4 improved dp/dt min, as compared to ExoCTRL and PBS group.
In vitro, ExoCXCR4 was more bioactive than ExoCTRL in preventing CM death. This in vitro effect was
independent from SDF-1α, as shown by using AMD3100 as specific CXCR4 antagonist. We showed,
for the first time, that systemic administration of Exo derived from CXCR4-overexpressing CPC
improves heart function in a rat model of ischemia reperfusion injury These data represent a
substantial step toward clinical application of Exo-based therapeutics in cardiovascular disease.
Keywords: exosomes; CXCR4; cardiac progenitor cells; intravenous injection
1. Introduction
Over the past 20 years, cell-therapy approaches have been investigated as an exciting strategy
to repair heart tissue after myocardial infarction (MI) [1–3]. Today the prevailing view is that stem
and progenitor cells elicit their therapeutic effects via indirect paracrine mechanisms that result
in the salvage of myocardium at risk, rather than cardiac regeneration by trans-differentiating
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into cardiomyocytes (CM) [1,4]. This notion implies that therapeutic agents, including cells and
cell-derivatives, such as extracellular vesicles (EV), act within the context of cardioprotection, and
it would ideally be delivered as early as possible after acute MI [4]. In patients after acute MI,
intracoronary (IC) or systemic delivery of bio-therapeutics at very early time points, soon after
the percutaneous coronary angioplasty (for instance, as it has been implemented with systemic
thrombolysis) [5], would be desirable to achieve cardioprotection, while also minimizing the risk of
intramyocardial (IM) injections using a percutaneous catheter.
Recently data pointed to exosomes (Exo), nanosized EV formed into cytosolic sub-compartments,
as the main indirect mechanism of benefit of cardiac progenitor cells (CPCs) and other cell types,
such as bone marrow-derived mesenchymal stem cells (MSCs), into infarcted hearts [6–10]. Exo are
composed of a phospholipidic bilayer that encloses proteins, nucleic acids (mRNA, DNA, microRNA),
and lipids [11,12], which mediate a variety of intercellular signals [13,14]. In a porcine model of chronic
MI, Exo-CPC were shown to promote neovascularization and to decrease infarct size following IM,
but not IC administration [15]. It was hypothesized that these differences between the two routes of
administration might be due to limited Exo retention in the heart after IC delivery [15]. This raises the
question on how to enhance Exo homing to injured myocardium.
CXCL12 (also known as stromal cell-derived factor 1; SDF-1α) is a member of the CXC
chemokine family, which is overexpressed in ischemic tissues [16,17], including infarcted myocardium.
The expression of this chemokine in infarcted myocardium is upregulated because the activation of
hypoxia-induced factor-1(HIF-1) [18]. It has been shown that SDF-1α plasma levels are increased
in patients post-MI [17]. SDF-1α binds the CXCR4 receptor, acting as a potent chemoattractant for
CXCR4 expressing cells, including circulating progenitor cells [19]. This effect by SDF-1α play a role
in cardiac repair through the recruitment of circulating progenitor cells to the infarct zone [20,21].
To maximize the effect of SDF-1α for tissue regeneration, several groups have genetically engineered
MSCs to overexpress CXCR4, which resulted in enhanced MSC mobilization, engraftment, and cardiac
repair in vivo [22–24]. Kang K et al. showed that using an in vivo rat MI model, a cell sheet of MSCs
primed with Exo overexpressing CXCR4 (ExoCXCR4) was able to preserve heart function when applied
soon after coronary artery ligation, whereas the MSC sheet exposed to control Exo was ineffective.
These results indicated that MSC-derived ExoCXCR4 enhance MSC-mediated cardioprotection [25].
The in vivo direct effect of ExoCXCR4 by intravenous injection has not yet been tested. In our
design, we propose a systemic delivery of Exo rather than Exo-mediated priming of injectable cells.
To address this question, we engineered CPCs to overexpress CXCR4 (CPCCXCR4). Although CPC
share with MSC the expression of well-known surface markers, such as CD105, CD90, CD73, Exo
secreted by CPC resulted deeply different in terms of protein content and functional properties
compared to Exo-MSC [6]. Having recently described the cardioprotective activities of IM injected
Exo-CPC in a rat MI model [6], here we explored whether CPCCXCR4 –derived Exo exhibit superior
homing and cardioprotective effects, as compared to naturally occurring Exo injected via tail-vein.
We hypothesized that the formation of an SDF-1α gradient towards the heart following MI might
increase the bioavailability and the retention of ExoCXCR4 within the tissue. Particularly, we evaluated
the therapeutic efficacy of systemic ExoCXCR4 administration in an acute model of ischemia/reperfusion
(I/R). I/R model has recently been indicated as the most appropriate preclinical model for studying
cardioprotective strategies [26]. Additionally Exo homing to, and uptake by, CM was studied ex vivo
in isolated-perfused hearts. Finally, we also sought to confirm their cardioprotective properties in
human iPS-derived CM.
2. Results
2.1. CPCCXCR4 Load Exogenous Receptor into Exo at Protein and mRNA Levels
Although primary naïve CPC express the transmembrane receptor CXCR4 (CD184), this is poorly
expressed on the surface of Exo secreted by these cells. Therefore, we used PCMV3-Cx-Myc plasmid
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in an attempt at enriching cells and Exo for hCXCR4 receptor. Transfection significantly increased
expression of CXCR4 in cells (CPCCXCR4) in comparison to CPC transfected with empty backbone
(CPCCTRL), as verified by flow-cytometer (FC) and western blot (WB) analyses (Figure 1a,b). CXCR4
could be detected on Exo secreted by CPCCXCR4 (ExoCXCR4) and slightly onto surface of Exo derived
from CPCCTRL (ExoCTRL) (Figure 2a,b). The level of expression of CXCR4 in ExoCTRL was comparable
to naïve expression of this receptor with no increment due to the transfection of backbone plasmid
(Figure A1e).
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performed using two different antibodies directed against both the N-terminus (extraluminal-
domain) and the C-terminus (intraluminal-domain) region in the absence of permeabilization. Only 
the anti-N-terminus CXCR4 antibody resulted in a positive staining (Figure 2c). Data was confirmed 
by Cryo Electron Microscopy (Cryo-EM) analysis and immunogold staining experiment, using anti-
CXCR4 (N-terminus) as a primary antibody (Millipore) (Figure 2d). 
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Figure 1. The hCXCR4 expression. (a) Flow cytometer analyses for relative expression of hCXCR4
(CD184) in control CPC (CPCCTRL, purple histogram), and CXCR4 overexpressing CPC ( PCCXCR4,
blue histogram). Quantitative data are percentage of positive cells (n = 6 patients/group) * p < 0.05
(two-tailed, paire Student t-test). (b) Western blot showing expression of XCR4 in CTRL vs.
CPCCXCR4. Quantitativ data are r lative xpression levels (densitometry) of CXCR4 normalize for
β-actin and showed as fold-changes to CPCCTRL (n = 6 patients/group) * p < 0.05 (two-tailed, paired
Student t-test).
To verify the correct transmembrane orientation of the receptor in ExoCXCR4, FC analysis was
performed using two different antibodies directed against both the N-terminus (extraluminal-domain)
and the C-termin (intraluminal-domain) region in the bsence of permeabilization. Only the
anti-N-terminus CXCR4 antibod resulted in a positive staining (Figure 2c). Data wa confirmed
by Cryo Elect on Microscopy (Cryo-EM) ana ysis and immunogold staining experiment, using
anti-CXCR4 (N-terminus) as a primary antibody (Millipo e) (Figure 2d).
In order to det rmine t e presence of endog nous versus exogenous CXCR4 mRNA in Exo,
we constructed 2 primer pairs that specifically amplified the hCXCR4 sequence only (pairs 1,2,
Figure A1) and the hCXCR4 sequence with the fused c-Myc tag (pairs 1–3, Figure 2e). The hCXCR4
mRNA was slightly detectable in ExoCTRL and dramatically increased in ExoCXCR4. Only ExoCXCR4
Int. J. Mol. Sci. 2019, 20, 468 4 of 24
contained the exogenous sequence as evidenced by the presence of the c-Myc tag amplicon (Figure 2e).
By WB analysis, ExoCTRL and ExoCXCR4 expressed similar levels of the Exo specific marker TSG-101
(Figure 2b), and tetraspanins (CD63, CD9, CD81) by FC analysis (Figure 2f). The expression of
functional pregnancy-associated plasma protein-A (PAPP-A), previously showed to be functional into
Exo-CPC [6], was similar in ExoCTRL and ExoCXCR4 (Figure A1d). Moreover, the overexpression of
CXCR4 does not impair size/concentration distributions of Exo, as assessed by Nanosight analysis
(Figure 2g).
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Figure 2. CXCR4 expression. (a) Quantitative data flow cytometer analyses for relative expression
of CXCR4 in ExoCTRL (purple bar), and CXCR4 overexpressing Exo (ExoCXCR4, blue bar). Exo were
bound to beads before analyses as described in the method section. Data are fold-changes in mean
Int. J. Mol. Sci. 2019, 20, 468 5 of 24
fluorescence intensity (MFI) versus controls (n = 7 patients/group) * p < 0.05 (two-tailed, paired
Student t-test). (b) Western blot showing expression of CXCR4 in ExoCXCR4 vs. ExoCTRL.
Quantitative data are relative expression levels of CXCR4 normalized for TSG101 and showed as
fold-changes to ExoCTRL (n = 4 patients/group). (c) Bead-based flow cytometric analysis for Exo.
Two different antibodies directed against the N-terminus (extraluminal-domain) and the C-terminus
(intraluminal-domain) region of hCXCR4 (CD184) were used in the absence of permeabilization.
Only the anti-N-terminus CXCR4 antibody resulted in a positive staining, as shown by the right-shift of
bead-Exo complex. (d) Cryo-EM image of ExoCXCR4 immunolabeled with rabbit CXCR4 as a primary
Ab, and goat-anti-Rabbit IgG 25 nm gold conjugate as a secondary Ab, showing CXCR4 on the surface
of a particle. (e) The hCXCR4-mRNA expression. Conventional RT-PCR showing the presence of
hCXCR4 mRNA in Exo. The exogenous sequence (c-Myc) is only present into ExoCXCR4. Primers
used for individual PCR assays, are indicated by numbers in brackets in the Appendix A Figure A1.
(f) Expression of the exosome markers, CD9, CD63, and CD81, as assessed by flow cytometry in ExoCTRL
purple dots), and ExoCXCR4 (blue dots). (g) Size distribution of Exo. Averaged Size/Concentration
of ExoCTRL (n = 10 repeated measurements of 3 different patients) and ExoCXCR4 (n = 10 repeated
measurements of 3 different patients). Red error bars indicate +/− SE of the mean.
2.2. Intravenous Injection of ExoCXCR4, but not ExoCTRL, Is Protective after In Vivo I/R Injury
Since our experimental hypothesis was based on the important role of the CXCR4-SDF-1α axis in
cardiac repair, we empirically assessed the SDF-1α levels into myocardial tissue at different time-points
following myocardial I/R injury (Figure A2). The chemokine was picked at three h after reperfusion;
this time-point was chosen for the in vivo tail vein injection of Exo (Figure 3a). ExoCXCR4, but not
ExoCTRL, improved left ventricular ejection fraction (LVEF) at 7 days (Figure 3b). Both types of Exo
significantly improved LVEF at 4 weeks, as compared to PBS-injected control rats (75.0 ± 1.4% and
63.5 ± 2.5% for ExoCXCR4 and ExoCTRL, respectively, versus 53.7 ± 1.1% in the PBS group; p < 0.01
and p < 0.05 respectively). ExoCXCR4 was significantly more effective than ExoCTRL in this regard
(p < 0.01). Parallel changes in end-systolic and end-diastolic LV volumes were observed (Figure 3c,d).
Hemodynamic measurements showed that ExoCXCR4 significantly improved –dp/dt min. Although
not statistically significant, a trend toward the dp/dt max improvement was also observed in ExoCXCR4
group. ExoCTRL improved –dp/dt min only slightly, as compared to the PBS group (Figure 3e). From
LV pressure/volume loops, the time constant of isovolumic LV pressure fall (Tau) properties was
significantly reduced in hearts injected with ExoCXCR4. The whole set of hemodynamic data indicated
a global improved in diastolic relaxation (Figure 3f) for hearts injected with ExoCXCR4. Finally, hearts
in the ExoCXCR4 group displayed smaller scars than those in the ExoCTRL or PBS groups (Figure 4a).
There also was a significant reduction of scar size in the ExoCTRL group vs. PBS. Both ExoCTRL and
ExoCXCR4 increased blood vessel density (Figure 4b) at a similar level.
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Figure 3. In vivo cardio-protection after I/R. (a) Scheme depicting the study protocol. I/R model was
induced by ligating the left descending anterior coronary that was then released after 30 min. Exo
(2 × 1011 total particles from a pool of n = 6 patients, in 300 µL PBS) were injected tail vein 3 h after
reperfusion. (b) ExoCXCR4 but not ExoCTRL significantly improved LVEF at 7days after I/R, compared
to PBS control group. At 28 days after I/R, ExoCXCR4, and to a lesser extent ExoCTRL, significantly
improved LVEF compared to control group (n = 6 rats/group), # p < 0.05 (one-way analyses of
variance-ANOVA with post-hoc multiple comparisons using the Tukey-Kramer multiple comparisons
test for paired parametric comparisons; test was performed at each time-point). (c,d) ExoCTRL reduced
both left ventricle (LV) end-systolic volume (LVESV) and left ventricle end-diastolic volume (LVEDV)
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was significantly less than modified Exo CXCR4 (n = 6 rats/group), # p < 0.05 (one-way analyses of
variance-ANOVA with post-hoc multiple comparisons using the Tukey-Kramer multiple comparisons
test for paired parametric comparisons; test was performed at each time-point). (e) Hemodynamic
measurements showing a decreased ventricular compliance in the ExoCXCR4 by quantitative analysis
of –dp/dt min and dp/dt max (n = 6 rats/group for ExoCTRL and ExoCXCR4; n = 5 rats/group PBS)
# p < 0.05 (one-way analyses of variance-ANOVA with post-hoc multiple comparisons using the
Tukey-Kramer multiple comparisons test for paired parametric comparisons; test was performed at
each time-point). (f) From LV pressure/volume loops, the time constant of isovolumic LV pressure fall
(Tau) value, which reflects diastolic relaxation properties, was calculated. LV relaxation was improved
and time constant reduced in the ExoCXCR4 (n = 6 rats/group) group compared with the ExoCTRL
(n = 6 rats /group) and PBS (n = 5 rats/group) # p < 0.05 (one-way analyses of variance-ANOVA
with post-hoc multiple comparisons using the Tuke–Kramer multiple comparisons test for paired
parametric comparisons).
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Figure 4. (a) asson’s Trichro e staining for the quantification of infarct size. Exo reduce scar size at
28 days after I/R. The reduction in scar size is more pronounced in ExoCXCR4 co pared to ExoCTRL
treated group (n = 5 rats/group PBS, n = 6 rats/group ExoCTRL and ExoCXCR4). (b) ExoCTRL and Exo
CXCR4. increased blood vessel density. SMA, smooth muscle actin (green); TnI, Troponin I (red); nuclear
counterstaining (blue); n = 4 rats/group PBS, n = 6 rats/group ExoCTRL and ExoCXCR4). # p < 0.05
(one-way analyses of variance-ANOVA with post-hoc multiple comparisons using the Tukey–Kramer
multiple comparisons test for paired parametric comparisons).
2.3. ExoCXCR4 Is Delivered More Efficiently than ExoCTRL to CM in Ischemic/Reperfused Rat Hearts Ex Vivo
To assess whether the superior in vivo cardioprotective effect of ExoCXCR4 is mediated by increased
cardiac homing as a result of SDF-1α upregulation in the injured heart, rat hearts were subjected
to in vivo I/R injury. Three hours later, hearts were harvested and perfused retrogradely in a
Langendorff-mode (Figure 5a). Equal amounts of ExoCXCR4celmiR39 or ExoCTRLcelmiR39 (see Section 4)
were added to the perfusates in the two groups, and hearts were continuously perfused for 2 h. CM
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were then isolated from hearts perfused ex vivo, and cel-miR39 levels were determined in the isolated
CM as a measure of Exo delivery. ExoCXCR4celmiR39 perfused hearts showed increased cel-miR39
levels compared with both ExoCTRLcelmiR39 and PBS-perfused control hearts (fold-increase vs. PBS:
162.6± 42.6 and 7.7± 1.7 for ExoCXCR4celmiR39 and ExoCTRLcelmiR39 respectively; Figure 5b). In addition,
hCXCR4/c-Myc mRNA was detectable in adult CM from hearts perfused with ExoCXCR4celmiR39, but
not in those receiving ExoCTRLcelmiR39 (Figure 5c). These results indicate that following in vivo I/R
injury ExoCXCR4 is delivered to CM in injured hearts more efficiently than ExoCTRL.
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rat and 3 h later hearts were excided and retrogradely perfused in a langendorff system for a subsequent
2 h. ExoCTRLcel-miR39 and ExoCXCR4cel-miR39 were added to the perfusates. PBS was added to the control
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perfusing solution. (a) ExoCXCR4cel-miR39 containing perfusates showed increased cel-miR39 levels
compared with ExoCTRLcel-miR39 and PBS perfused control hearts. Data are 2−∆∆Ct values vs.
PBS-perfused hearts (n = 5 patients/group) # p < 0.05 (two-tailed, paired Student t-test). (b) Western
blotting analyses on cell lysate of isolated adult CM. The levels of ERK1/2 phosphorylation was
increased into CM ExoCXCR4cel-miR39 from isolated rat hearts. (c) TUNEL staining. TUNEL-positive
(green nuclei) of apoptotic CM (α-SA -positive cells; red). The α-SA mask is used to detect nuclei
within CM on DAPI fluorescence. Quantitative data are expressed as number of green on total CM
nuclei, # p < 0.05 (one-way analyses of variance-ANOVA with post-hoc multiple comparisons using the
Tukey-Kramer multiple comparisons test for paired parametric comparisons).
2.4. ExoCXCR4 Shows Superior Ex Vivo Cardioprotective Effects Compared with ExoCTRL
Having previously showed that Exo act mostly through MAP kinases pathway [6], we evaluated
whether ERK1/2 phosphorylation was improved in adult CM isolated from ex vivo experiments.
CM isolated from infarcted and perfused hearts were lysed for WB analysis. ExoCXCR4celmiR39 was able
to significantly induce ERK1/2 phosphorylation after 2 h of perfusion as compared to PBS perfused
hearts (Figure 5b), whereas ExoCTRLcelmiR39 was less effective in this regard.
To confirm cytoprotective role of Exo a subset of isolated adult CM were plated on glass coverslip
and soon after fixed for TUNEL staining. Both ExoCTRLcelmiR39 and ExoCXCR4celmiR39 increased the
number of surviving CM after 2 h of perfusion as compared to PBS group. The number of adult
CM undergoing apoptosis was lower in ExoCXCR4 than ExoCTRL, although not statistically significant
(Figure 3c).
2.5. ExoCXCR4 Shows Superior In Vitro Cardioprotective Effects Compared with ExoCTRL
ExoCTRL is cytoprotective in neonatal HL-1 [6,7]; here we compared its cytoprotective activity
with that of ExoCXCR4 using the in vitro model of staurosporine-induced death in HL-1 cardiomyocytes.
ExoCXCR4 was more effective than ExoCTRL in preventing staurosporine-induced death in HL-1 cells
(ExoCXCR4 94.7 ± 2.6%; ExoCTRL 80.9 ± 1.8%) (Figure 6a,b). Similar results were obtained in human
iPSC-derived CM, as ExoCXCR4 was more effective than ExoCTRL at preventing staurosporine-induced
death in these cells (ExoCXCR4 73.0 ± 2.7%; ExoCTRL 58.6 ± 1.2%; Figure A3). Furthermore, the effect of
ExoCXCR4 in HL-1 cells was not antagonized by ADM3100, indicating that is was independent from
SDF-1α (Figure 6c). Similar intracellular levels of celmiR39 was observed in normal or stress conditions
when ExoCXCR4celmiR39 and ExoCTRLcelmiR39 were added to the media of HL-1 cells; indicating that
the presence of CXCR4 on Exo surface did not increase in vitro uptake (Figure 6d). This finding is
probably related to the absence of an SDF-1α gradient in this in vitro model, as opposed to the in vivo
situation, as shown by WB in vitro analysis (Figure A2b). Both ExoCTRL and ExoCXCR4 induced ERK1/2
phosphorylation after staurosporine-induced damage. Compared with ExoCTRL, ExoCXCR4 treated
HL-1 showed higher levels of phosphorylated ERK1/2 in both staurosporine-induced (Figure 7a) and
normal (Figure A4c) conditions. The effect was prevented by adding the kinases chemical inhibitor
U0126 (Figure 7b). In parallel, U0126 was able to abolish ExoCXCR4 protective effect on HL-1 CM
(Figure 7d). This finding is in line with our previous data [6], showing that the ERK pathway is
involved in the anti-apoptotic effect mediated by Exo.
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not affected by the addition of AMD3100 as specific CXCR4 antagonist. (d) In vitro Exo uptake. Real-
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patients/group). 
Figure 6. In vitro bioactivities of ExoCXCR4. (a,b) ExoCTRL, and ExoCXCR4 inhibit staurosporine-induced
death in HL-1 CM (green) (n = 6 patients/group for ExoCTRL and ExoCXCR4; n = 5 repeated
measurements for PBS and FBS) # p < 0.01 (one-way analyses of variance-ANOVA with post-hoc
multiple comparisons using the Tukey-Kramer multiple comparison tests for paired parametric
comparisons). ExoCXCR4 exhibit superior pro-survival effect. (c) ExoCXCR4 superior pro-survival
effect in HL-1 CM is not affected by the addition of AMD3100 as specific CXCR4 antagonist. (d) In vitro
Exo uptake. Real-time PCR analyses of cel-miR39 (mature sequence) levels in HL1 CM incubated with
ExoCTRLcel-miR39 and ExoCXCR4cel-miR39 during normal or stress conditions. Data are 2−∆∆Ct values vs.
PBS (n = 5 patients/group).
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chemical inhibitor U0126. (n = 5 patients/group for ExoCTRL and ExoCXCR4; n = 5 repeated measurements 
for PBS) # p < 0.01 (one-way analyses of variance-ANOVA with post-hoc multiple comparisons using 
the Tukey-Kramer multiple comparisons test for paired parametric comparisons). (c) Human 
recombinant SDF-1α is able to stimulate CXCR4 receptor in mouse HL-1 CM only after these cells 
have uptaken the human receptor from Exo (n = 5 patients/group); * p < 0.05 (two-tailed, paired 
Student t-test). (d) Exo CXCR4 are significantly less effective in preventing staurosporine cell death when 
HL1 CM are treated with the kinases chemical inhibitor U0126, (n = 5 patients/group for ExoCXCR4 and 
Figure 7. (a) estern blot showing pro-survival ERK1/2 phosphorylation in HL-1 CM when ExoCTRL,
and ExoCXCR4 were added to the medium in stress-conditions (n = 4 patients/group) # p < 0.01
(Kruskal-Wallis test nonparametric multiple comparisons with Dunn’s multiple comparison test);
* p < 0.05 (two-tailed, paired Student t-test). (b) ERK1/2 phosphorylation is prevented by adding the
kinases chemical inhibitor U0126. (n = 5 patients/group for ExoCTRL and ExoCXCR4; n = 5 repeated
measurements for PBS) # p < 0.01 (one-way analyses of variance-ANOVA with post-hoc multiple
comparisons using the Tukey-Kramer multiple comparisons test for paired parametric comparisons).
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(c) Human recombinant SDF-1α is able to stimulate CXCR4 receptor in mouse HL-1 CM only after
these cells have uptaken the human receptor from Exo (n = 5 patients/group); * p < 0.05 (two-tailed,
paired Student t-test). (d) Exo CXCR4 are significantly less effective in preventing staurosporine cell
death when HL1 CM are treated with the kinases chemical inhibitor U0126, (n = 5 patients/group
for ExoCXCR4 and ExoCXCR4+U0126; n = 4 repeated measurements for PBS ) # p < 0.05 (one-way
analyses of variance-ANOVA with post-hoc multiple comparisons using the Tukey-Kramer multiple
comparisons test for paired parametric comparisons). Cell vitality was not affected by U0126 alone
(n = 4 repeated measurements).
2.6. ExoCXCR4 Transfers CXCR4 mRNA and Protein into CM In Vitro
We hypothesized that the superior cytoprotective in vitro effect of ExoCXCR4 was due to the
transfer of bioactive CXCR4 to target cells that may enhance the previously described cytoprotective
effect of Exo (which also includes PAPP-A mediated protease activity) [6]. We tested the presence
of exogenous hCXCR4 in murine HL-1 CM at mRNA and protein levels. The hCXCR4-mRNA was
detected in HL-1 CM exposed to ExoCXCR4 but not in those exposed to ExoCTRL. Moreover, the c-Myc
nucleic acid sequence within the hCXCR4-c-Myc construct was detected by RT-PCR in cells exposed to
ExoCXCR4 but not in those exposed to ExoCTRL (Figure A4a). This observation was made both under
basal conditions and after staurosporine-induced cell stress (Figure A4a). The c-Myc tag was detectable
at the protein level in CM treated with ExoCXCR4, demonstrating the translation of the hCXCR4-c-Myc
fusion construct, but not in those receiving ExoCTRL (Figure A4b). These results demonstrate the
ability of ExoCXCR4 to deliver the mRNA encoding for the exogenous hCXCR4, which may result in
the translation of hCXCR4 protein in mouse CM. Because hCXCR4 bioactivity requires the presence of
SDF-1α [18], we used a species-specific human recombinant SDF-1α protein (hDF-1α) that does not
activate the downstream ERK signal in mouse HL-1 cells in order to assess hCXCR4 bioactivity in these
cells (Figure 7c). HL-1 cells pre-treated with ExoCXCR4, but not pre-treated with ExoCTRL, exhibited
increased ERK1/2 phosphorylation after the subsequent exposure to hDF-1α (Figure 7c). These results
indicate that ExoCXCR4 delivers bioactive hCXCR4 to target cells.
3. Discussion
Exo have emerged as a therapeutic tool with the potential to replace cellular approaches in the
treatment of cardiovascular disease [6,7,27,28]. Compared with cell therapy, Exo offer several potential
advantages, as they can be stored at −80 ◦C without a substantial loss of functional activity [6,7,29],
they are effective after systemic delivery [30], with a dosage that is not limited by microvascular
plugging [31], and they are poorly immunogenic [32]. With respect to therapeutic applications, safety
and efficacy of Exo depend on their bio-distribution that influence selective and effective uptake,
respectively, by target cells after systemic delivery [33]. In fact, a given Exo is taken up with different
efficiencies by different recipient cell types [34]. Systemically delivered Exo is largely up taken by
the liver, and to lesser extents by spleen and lungs [35–37], although in vivo Exo bio-distribution
also depends on the producing cell type [12]. In animal models of ischemic heart disease, IM Exo
administration was beneficial in several studies [6–8], whereas IC Exo administration was tested in a
single study [15]. The latter found that IM delivered Exo from CPCs, but not IC delivered Exo from
the same producing cells were beneficial in a pig MI model, mainly due to comparatively lower Exo
retention in the heart using the IC route of administration. From a translational perspective, IM Exo
injection would hardly be feasible for treating acute MI patients, thus, improving Exo retention by the
heart after IC or systemic administration is a crucial goal. Recently studies have attempted to engineer
transmembrane proteins of Exo using “cardiac-homing peptide” to increase targeting capability to
cardiac tissues [38–40]. These study showed that homing peptides displayed on the external part of
Exo, although not directly implicated into mechanism of action of Exo, promote the specificity and
efficiency of systemic delivery of Exo.
Our experimental approach leverages on the important role of the CXCR4-SDF-1α axis in
cardiac repair. SDF-1α is markedly upregulated within 1 h of myocardial ischemia, resulting in
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a chemoattractant gradient for CXCR4 expressing leukocytes and stem cells [41]. Within the heart,
SDF-1α expression was demonstrated for both CM and fibroblasts a few hours after acute MI [41].
In light of the above, we hypothesized that beside the physiological ischemia-induced cardiac SDF-1α
expression, overexpressing CXCR4 in Exo would result in an enhanced homing of Exo to the injured
myocardium, and thus, increased cardioprotective effects. To test this hypothesis, we genetically
modified CPCs to overexpress CXCR4 and then isolated the secreted Exo. CXCR4 was detectable
on ExoCXCR4 but not on ExoCTRL released from naive CPCs. Exo homing to, and uptake by, CM
was studied ex vivo in isolated-perfused hearts after in vivo I/R injury. ExoCXCR4 were markedly
more effective than ExoCTRL in this regard. It should be emphasized that Exo uptake was specifically
studied in CM isolated from ischemic rat hearts, as opposed to the total heart cell population. We did
not evaluate and discriminate Exo uptake by other cell types within the ischemic heart, such as
fibroblast and endothelial cells. This represents a limitation of the study, however, we have evidence
showing that the benefit of ExoCXCR4 and its superior effect as compared to ExoCTRL results in an
increased number of surviving cardiomyocytes (Figures 4a and 5c) rather than improved angiogenesis
(Figure 4b), for which we did not find any significant difference between the groups. Exo uptake
measured here includes both homing to I/R heart tissue and CM binding and uptake. These different
components of the global “uptake” process cannot be discriminated. For instance, enhanced Exo
homing to injured myocardium would increase Exo bioavailability in the extracellular compartment,
and therefore on the CM surfaces, and result in an increase in total Exo uptake by CM, even in the case
when the intrinsic Exo uptake efficiency (i.e., the intrinsic efficiency of the process at a single particle
level) was unaffected. In vivo, we similarly found superior functional benefits in terms of scar size as
well as LV systolic and diastolic function for ExoCXCR4 compared with ExoCTRL. Efficient ExoCXCR4
homing to I/R myocardium, as demonstrated in ex vivo isolated-perfused hearts, most likely played
an important role in vivo, too.
Although the increased concentration of SDF-1α cytokine within the heart tissue may enhance
bio-availability of Exo in close proximity of CM surface, it does not have a direct effect in mediating
the uptake in vitro, where the experimental conditions failed to recapitulate in vivo cytokines gradient
(Figure 6a). Indeed, the use of a specific CXCR4 antagonist (AMD3100) has no effect on increasing
Exo uptake, neither inhibits protection, in vitro. On the other hand, the transfer of active and
SDF-1α-responsive receptor from Exo to target cells, as shown in the Figure 7c, plays a crucial role
leading to activation of protective signaling pathways, and in addition is of the already described
mechanisms via PAPP-A–mediated IGF-1 release [6]. As expected, the degree of Exo-mediated
improvement of cardiac function, previously shown by our group upon IM injection into infarcted
hearts [6], could not be matched by the tail-vein injection, likely due to larger in vivo biodistribution.
Indeed, at seven days after tail-vein injection of ExoCTRL we did not achieve statistically significant
improvement compared to saline group (Figure 7), as was the case by IM injection in previous
studies [6,7]. By enhancing homing of Exo to CM via CXCR4 expression on the vesicle surface, we
achieved comparable functional improvements using IM and systemic routes of administrations
(Figure 3). Previous studies have shown that mesenchymal stem cells (MSCs) overexpressing surface
CXCR4 improve migration and engraftment in response to SDF-1α gradients in various disease
models [42–44]. Taking a methodological approach similar to the one used here, Kang et al. [25]
recently showed that Exo secreted from CXCR4 overexpressing MSCs mediated antiapoptotic and
proangiogenic effects in vitro, while also indirectly enhancing MSC-mediated CM survival in vivo.
Here, we investigated for the first time the direct effects of systemic ExoCXCR4 injection and
established Exo homing/uptake as a crucial mechanism by which CXCR4 increases Exo-CPC delivery
to CM. ExoCXCR4 not only transfer their exogenous protein to the target cells, they are also able
to transfer the mRNA, and this confirmed data obtained from different groups [45]. The relative
contribution of bioactive CXCR4 versus the transduction of its mRNA by Exo receiving cells has not
been detailed in the present study. From the functional point of view, ExoCXCR4 have superior in vitro
and in vivo anti-apoptotic effects in CM compared to ExoCTRL. These results have major translational
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implications for treatment of acute MI patients, owing to the major advantages associated with systemic
drug administration [25], which can be performed upon recanalization of the culprit artery.
4. Materials and Methods
4.1. Cell Culture
Right cardiac atrial appendage specimens were obtained from patients (n = 13) who underwent
surgical repair of heart valve disease and gave written informed consent. Protocols used in this study
were approved by local Ethical Committee for Clinical Research (Comitato Etico Cantonale, Bellinzona,
Switzerland; Rif. CE 2923), and study was performed according to the Declaration of Helsinki. CPCs
were derived from atrial specimens, as described [6]. Briefly, atrial specimens were cultured as
primary ex vivo tissue explants in basic Iscove’s modified Dulbecco’s medium (IMDM; Lonza, Basel,
Switzerland) supplemented with 20% fetal bovine serum (FBS) and 1% v/v penicillin-streptomycin
(Life Technologies, Europe BV, Zug, Switzerland). The cellular outgrowth of atrial explants was
collected within 14 days and seeded into fibronectin-coated 25 mL flasks, forming a monolayer of
CPCs that were passaged twice by trypsinization before Exo purification from conditioned media.
Mouse HL-1 cardiomyocyte cell line (LSU Health Sciences Center, New Orleans, LA, USA) was
grown in Claycomb Medium (Sigma, Merck KGaA, Darmstadt, Germany) supplemented with 100 µM
norepinephrin, 10% FBS, 1% v/v penicillin/streptomycin, and 4 mM L-glutamine [46]. AMD3100
(Millipore, Merck KGaA) at the concentration of 10 µM was used as specific CXCR4 antagonist.
For experiments performed to establish the bioactivity of human CXCR4 into target cells (Figure 7c),
confluent HL-1 were treated with human recombinant SDF-1α chemokine (hDF-1α, Sigma) at the
concentration of 100 ng/mL for 40 min. The kinases chemical inhibitor U0126 monoethanolate (Sigma)
at the concentration of 20 µM was used to inhibit ERK1/2 phosphorylation; iPS-derived CM were
obtained as previously described [45]. Briefly CPC were reprogrammed through Sendai virus infection
using OCT3/4, SOX2, KLF4, and MYC (CytoTune™-iPS 2.0 Sendai Reprogramming Kit; Thermo
Fisher Scientific, Europe BV, Zug, Switzerland), according to manufacturer’s instructions. Cardiac
differentiation of iPSCs was induced using the GibcoTM PSC Cardiomyocyte Differentiation Kit
(Thermo Fisher Scientific). Differentiated cells were maintained in RPMI (Gibco, Thermo Fisher
Scientific) supplemented with B27 (Gibco) at 37 ◦C and 5% of CO2 and changed every two days.
4.2. CPC Engineering to Overexpress CXCR4
The human sequence of CXCR4 (NM_001008540) was cloned into PCMV3-C-Myc expression
plasmid (Sino Biological Inc., Wayne, PA, USA) to encode the hCXCR4 cDNA fused with c-Myc
tag under the transcriptional control of a CMV promoter (PCMV3-Cx-Myc). This vector was used
to transfect CPCs (CPCCXCR4). Control CPC (CPCCTRL) were transfected with an empty backbone
plasmid. Briefly, CPCs were gently collected by trypsinization and re-suspended in normal growth
medium at the density of 1 × 105 cells/mL. The transfection agent Lipofectamine 3000 was diluted in
Opti-MEM I medium (both from Thermo Fisher Scientific) and left for 10 min at RT. PCMV3-Cx-Myc
plasmid or empty backbone were diluted in Opti-MEM I medium and P3000 reagent (2 µL/µg DNA).
After incubation, the mix with Lipofectamine 3000 Reagent was added to the mix, containing the
diluted plasmid and incubated for an additional 10 min at RT. The mixture was then gently rocked and
incubated at 37 ◦C, 5% CO2. Two days after transfection, cells were washed several times with PBS
and the growth medium was exchanged with Exo-producing medium (DMEM high-glucose, Thermo
Fisher Scientific).
4.3. Particle Purification
Media conditioned by CPCCTRL and CPCCXCR4 were obtained by culturing cells in Exo-producing
medium in absence of serum for 7 days [6]. For particle purification, conditioned medium (10 mL)
was centrifuged at 3000 g for 15 min, filtered through a 0.2 µm membrane (BD Biosciences, Allschwil,
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Switzerland), centrifuged at 10000 g for 15 min, and then ultracentrifuged at 100000 g for 4 h. Exo
pellets were re-suspended in 100 µL PBS, pH 7.4, and stored at −80 ◦C. Particle number and size were
measured using NanoSight technology (Malvern Instruments, Malvern, UK).
4.4. Flow Cytometry
CPCCTRL and CPCCXCR4 were labelled with phycoerythrin (PE)-conjugated antibody anti-CXCR4
(CD184) (eBioscience, Thermo Fisher Scientific) and analyzed by means of direct immunofluorescence
with a Cytoflex flow cytometer (Beckman Coulter, Nyon, Switzerland). Isotype-matched, nonreactive
fluorochrome-conjugated antibodies were used as controls. Surface antigen markers expressed on
Exo were analyzed as described [6]. Briefly, exosomes were incubated with a mix of microbeads
coated with anti-CD63, anti-CD9, and anti-CD81 and anti-EPCAM antibody (JSR), and then with
fluorochrome-conjugated Abs against CD63, CD9, CD81 (all from BD Biosciences), and anti-CXCR4
(CD184) extracellular (Alomone, Jerusalem, Israel) or anti-CXCR4 intraluminal (Abcam, Cambridge,
UK). Beads incubated with in the absence of Exo served as controls. The resulting data were processed
using Kaluza™ analysis software (Beckman Coulter, Nyon, Switzerland).
4.5. Immuno-Gold Labeling and Cryo-Electron Microscopy(Cryo-EM)
For cryo-EM, isolated exosomes were resuspended in 30 mM HEPES, pH 7.4, containing 100 mM
KCl. Immuno-gold labelling was done by successive incubations of the exosome solution with
1:10 anti-CXCR4 antibody (Millipore) overnight, at 4 ◦C, then with 1:25 of either 15 and/or 25 nM
gold-conjugated goat Anti-Rabbit secondary antibodies (Aurion), for 3 h, at room temperature.
A 4–5 µL drop was deposited on glow-discharged 200-mesh copper grids with 2 µm holes (Quantifoil
R2/2, Quantifoil Micro Tools, Großlöbichau, Germany), then plunged frozen in liquid ethane using a
Leica EM-GP (Leica Microsystems, Wetzlar, Germany), at 90% humidity. For examination, all grids
were transferred under liquid nitrogen to a Gatan 626 cryo-holder (Gatan). Imaging was done under
low-dose conditions (~10 e- per Å2) by means of a 4k × 4k Ceta camera, on a FEI Talos 200C S/TEM
(FEI Company), operated at 200 keV. Images were acquired at nominal magnifications of 36,000×
and 45,000×, and at 3 to 5 µm underfocus, giving a final object sampling of 4.1 and 3.2 Å per
pixel, respectively.
4.6. Protein Isolation and Western Blot Analyses
Total proteins were extracted by lysing Exo or cells with ice-cold RIPA buffer (25 mM Tris pH 7.4,
150 mM NaCl, 1 mM EDTA, 1% Igepal CA 630, 1% Na-deoxycholate, 0.01% sodium dodecyl sulfate;
SDS) supplemented with protease inhibitors (SIGMAFAST™ Protease Inhibitor Tablets; Sigma) for
30 min at 4 ◦C under agitation. Exosome and cell lysates were centrifuged at 9500 g for 15 min at 4 ◦C,
and protein concentrations were determined using the BCA kit (Sigma). Proteins were boiled with
Laemmli SDS sample buffer 6× (0.375M Tris-HCl pH 6.8, 12% SDS, 60% glycerol, 0.6 M DTT, 20%
(v/v) β-mercaptoethanol, 0.2% (w/v) bromophenol blue; VWR International, Dietikon, Switzerland),
separated on 4–20% Mini-PROTEAN®TGX™ Precast Gel (Bio-Rad Europe, Basel, Switzerland), and
transferred onto a PVDF membrane with a semi-dry transfer system (Bio-Rad Europe). The membranes
were first blocked for 1 hr in Odyssey Blocking Buffer (LI-COR Biosciences, Bad Homburg vor der
Höhe, Germany) diluted 1:1 in distilled water and supplemented with 0.2% Tween 20 (OBB-T), then
incubated with the appropriate primary Ab diluted in OBB-T at 4 ◦C overnight under gentle agitation.
The membranes were rinsed and then incubated with an IRDye® 680RD or 800CW goat anti-mouse
or goat anti-rabbit secondary Ab (LI-COR Biosciences; 1:15000 dilution in OBB-T) at RT for 2 h.
The infrared signal was detected using the Odyssey CLx Detection System (LI-COR Biosciences).
Anti-TSG101 rabbit monoclonal Ab (1:1000) was from Abcam; anti-CXCR4 rabbit polyclonal Ab
(1:1000) was from Millipore, anti-β-actin mouse monoclonal HRP-conjugated Ab (1:25000) was from
Sigma, anti p-ERK, anti total ERK rabbit polyclonal Ab (1:1000) were from Cell Signalling, anti-SDF1-α
rabbit polyclonal (1:1000), and anti-GAPDH rabbit polyclonal (1:1000) were from Abcam. For the
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evaluation of ERK1/2 phosphorylation in adult CM isolated from ex vivo perfused hearts, total
proteins were extracted by lysing adult CM with ice-cold RIPA buffer supplemented with protease
inhibitors for 30 min at 4 ◦C under agitation. Western Blot analysis was performed using the protocol
described previously. Antibodies anti p-ERK, anti-total ERK rabbit polyclonal Ab (1:1000) were used.
The homodimeric active form of PAPP-A was specifically measured by dot immunoblotting under
non-denaturing conditions using mouse monoclonal 4PD4-PAPP30 antibody (HyTest, Turku, Finland).
4.7. In Vitro and Ex Vivo Exo Uptake by CM
To assess in vitro and ex vivo cellular uptake of Exo by CM, both CPCCXCR4 and CPCCTRL were
transfected with a pre-miRNA precursor for cel-miR-39 (Thermo Fisher Scientific), a C. elegans miRNA
not present in mammalian cells. Intracellular cel-miR39 levels can be used as a measure of cellular
uptake of cel-miR39 containing exosomes. Exo released from these cells are referred hereby as Exo
CXCR4celmiR39 (from CPCCXCR4) and Exo CTRLcelmiR39 (from CPCCTRL). In vitro HL-1 were incubated
with Exo CXCR4celmiR39 or Exo CTRLcelmiR39. CTRLcelmiR39 in normal conditions or after treatment with
staurosporine. Ex vivo isolated rat hearts were perfused in a Langendorff-mode using perfusates
supplemented with Exo CXCR4celmiR39 or Exo CTRLcelmiR39, and cel-miR-39 levels were measured in
HL-1 and primary adult rat CM using real-time RT-PCR. The level of expression cel-miR39 in the CPC
or Exo was consistent with dose-response efficiencies of transfection [6].
4.8. Levels of Exogenous mRNA into CM
PCR was performed using 2 pairs primers that specifically amplified the hCXCR4 sequence only
or the hCXCR4 sequence fused with c-Myc tag (1,2 for human CXCR4-mRNA; 1–3 c-Myc-mRNA;
see scheme in Figure A1). The murine sequence of CXCR4 receptor was not amplified by primers
(Figure A4), thus allowing the identification of mRNA carried by human derived Exo (hCXCR4-mRNA),
or overexpressed CXCR4 (c-Myc-mRNA).
4.9. In Vitro CM Viability Assay
To assess HL-1 CM viability, cells were seeded at a 6.25 × 104 cells/cm2 density in 96-well plates.
After 24 h, cell death was induced by 1µM staurosporine (Sigma). ExoCTRL or ExoCXCR4 (isolated
from conditioned media of cells from n = 6 patients) were added on top of staurosporine at the
3 × 106 particles/cm2 concentration, as assessed by Nanosight [6]. In some of the tested conditions,
the role of SDF-1α was tested by adding AMD3100 (10 µM) as CXCR4 specific antagonist. Twelve
hours later, cells were stained with Cellstain™ Double Stain Kit (Dojindo EU, München, Germany) for
30 min at 37 ◦C and counted under a fluorescence microscope.
Functional data were validated in human iPS-derived CM. Cell death was induced in iPS-CM
by 1 µM staurosporine (Sigma). ExoCTRL or ExoCXCR4 (isolated from conditioned media from
n = 5 patients) were added on top of staurosporine at the 3 × 106 particles/cm2 concentration,
as assessed by Nanosight. Twelve hours later, cells were stained with Cellstain™ Double Stain Kit
(Dojindo) for 30 min at 37 ◦C and counted under a fluorescence microscope.
4.10. RNA Extraction, Reverse Transcription and Real-Time PCR
Cells or exosomes were lysed with TRI Reagent (Sigma), and chloroform was added following
company instructions. The pellet was air-dried, re-suspended in DEPC water, and quantified with
NanoDrop™ 2000c (Thermo Fisher Scientific). For real-time amplification of cel-miR-39 sequence, 5ng
of specific RNA was reverse-transcribed using the Taqman miRNA reverse stem-loop primers (Applied
Biosystems, München, Germany) with a T100 Termal Cycler (Bio-Rad). Real-time PCR for specific
cell-miR-39 sequence was performed by adding to 1.33 µL cDNA: 1 µL 20× specific primer (Applied
Biosystems), 10 µL TaqMan Universal PCR Master Mix, and 7.67 µL DEPC water. Amplification and
detection of specific products were performed in triplicate using a CFX Connect™ Real-Time PCR
Detection System (Bio-Rad). Negative controls were included in each RT-PCR assay. The threshold
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cycle (Ct) of each gene was automatically defined and normalized to the control miR16 (∆Ct value) for
CPCs, HL-1 CM and exosomes, and to the control U87 or snoRNU202 for rats primary CM. Data are
shown as 2−∆∆Ct values.
For PCR amplification of hCXCR4 mRNA sequences, 500 ng of total RNA was reverse
transcribed using the GoScript™ Reverse Transcription System (Promega Madison, Dübendorf,
Switzerland). Before use for PCR, reactions samples were diluted 1:2 in DEPC water. PCR
was performed by adding to 2 µL cDNA, 4µL specific primer mix (1 µL primer forward:1 µL
primer reverse:1 µL DEPC water), 5 µL 5× Green Reaction buffer, 0.5 µL 10 mM dNTPs mix, and
0.125 µL Taq enzime. Samples were incubated at 95 ◦C for 2 min, 95 ◦C for 30 s and 60 ◦C for
30 s, 72 ◦C for 1 min, for 35 cycles. The following couple of primers were used: endogenous
human CXCR4 forward: 5-TCTGTGAGCAGAGGGTCCAG-3; reverse: 5-GCTGGAGTGAAAA
CTTGAAGACT-3. Exogenous human CXCR4-c-Myc forward 5-TCTGTGAGCAGAGGGTCCAG-3
reverse: 5-TCCTCTTCTGAGATGAGTTTCT-3.
4.11. Immunofluorescence and Histology
Cells were fixed with paraformaldehyde 4%, sucrose 2%, permeabilized with 0.5% Triton for
30 min and blocked with 5% serum for 30 min at 25 ◦C. Samples were then incubated with primary
antibodies in 5% serum direct against CXCR4 (Abcam 1/100), c-Myc tag (Abcam 1/200) overnight
at 4 ◦C. After 3× wash with PBS, each 10 min, Alexa Fluor secondary antibodies (Life Technologies,
1/1000) were used for detection. Images were acquired by a confocal microscopy system C2 Plus
(Nikon). Harvested hearts were cryo-preserved in optimal cutting temperature (OCT) medium at
−80 ◦C. For morphometric analysis, hearts were cut in 8-µm sections, and stained with Masson-
trichrome (HT15 Trichrome Stain Kit; Sigma) for measurement of scar size. On each heart section,
scar area was determined by tracing the infarct borders manually using ImageJ software (NIH Image,
Bethesda, MD, USA). Six sections distributed at fixed steps from the cardiac basis to the apex were
analyzed for each heart and values were averaged. Anti-SMA (1:100) (Santa Cruz, CA, USA), smooth
muscle actin, was used to stain vessels and TnI (1:100) (Santa Cruz, Santa Cruz, USA), Troponin I,
as marker for CM, on each heart section. The number of vessels and surface area were quantified using
ImageJ software. Six sections for each rat were used for the analysis and values were averaged.
4.12. SDF-1α ELISA
To assess the amount of SDF-1α protein on heart tissues of infarcted rats compared to control,
ELISA Kit for rat SDF1/CXCL12 was used (LS Bio, Seattle, WA, USA). Briefly, samples were directly
immobilized on to the wells of the microtiter plate. The detection (primary) antibody was added to the
wells for binding to its specific antigen for 1 h at 37 ◦C. After 3 washes, the Detection (secondary) Ab
was added and plate incubated for 30 min at 37 ◦C. A colorimetric substrate (Extra-sensitive TMB)
was used for the assay read-out. The accumulation of the coloured product is proportional to the
specific antigen present in each well. The results were quantitated with a microtiter plate reader at
450 nm absorbance.
4.13. TUNEL Assay
Adult CM isolated from ex vivo experiments were plated on glass coverslips and fixed with
paraformaldehyde 4%, permeabilized with 0.2% Triton for 5 min, and equilibrate at room temperature
for 5–10 min with Equilibration Buffer. Samples were then incubated with a solution of Nucleotide
Mix and rTdT Enzyme in a humidified chamber for 1 h at 37 ◦C and immersed in 2× SSC for
15 min at room temperature to terminate the reactions. After three washes to remove unincorporated
fluorescein-12-dUTP, cells were incubated with a primary antibody against alpha sarcomeric actinin
(1:100) and subsequently with an anti-mouse secondary antibody 568 (1:1000), both from Abcam and
with DAPI, and immediately analyzed under a fluorescence microscope. A positive control slide using
DNase I was included in each experiment.
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4.14. Animal Experiments
Experimental protocols were approved by the Animal Care Committee of Canton Ticino,
Switzerland (TI-08-18). All procedures conformed to the Directive 2010/63/EU of the European
Parliament. A model of myocardial ischemia with reperfusion was used. Ischemia Reperfusion
(I/R) was induced in healthy male Wistar rats (250–300 g body weight) anesthetized with a cocktail
of Ketamine (Ketasol 100, 100 mg/kg) and Xylazine (Rompun 2%, 80 mg/kg), intubated and
ventilated. The left anterior descending artery was ligated near its origin with a 6-0 prolene suture.
The coronary ligature was released after 30 min, and exosomes were injected in the tail-vein 3 h
after reperfusion with a total of 300 µL of PBS containing 2 × 1011 particles of the following vesicle
populations: pool of Exo-CPCCTRL (n = 6) and pool of Exo-CPCCXCR4 (n = 6) or PBS. The chest was then
closed, pneumothorax was reduced, and the rats were treated with Meloxicam during postsurgical
recovery. Sedated rats underwent transthoracic echocardiography at 7 and 28 days post-MI using
the Vevo2100 echocardiography system (VisualSonic System 2100, FUJIFILM VisualSonics, Toronto,
Canada) equipped with a 15-MHz linear transducer. Under ECG monitoring of heart rate, 2D images
of the hearts were acquired in long-axis views at the level of the greatest LV diameter. LV ejection
fraction (LVEF) was measured using Simpson’s analysis.
Hemodynamic analysis was performed at day 28 using a Millar pressure-volume conductance
catheter. Rats were anesthetized with an intraperitoneal injection of ketamine (Ketasol 100, 100 mg/kg)
and xylazine (Rompun 2%, 80 mg/kg). The trachea was cannulated, and the animal connected to a
positive- pressure volume-controlled rodent ventilator. The catheter was introduced through the right
carotid artery into the ascending aorta and then into the LV cavity. After hemodynamics measurements,
the animal was sacrificed.
4.15. Statistical Analyses
Results are presented as means ± SE of n independent experiments or patients from which
Exo producing cells were derived. Each single “n” is specified in the figure legends. Statistical
analyses were performed using InStat, version 3.0 (GraphPad Software, Inc., San Diego, CA, USA).
The hypothesis that data came from a normally distributed population was assessed using the
Kolmogorov Smirnov normality test. The assumption that data were sampled from populations
with identical SDs was tested using the method of Bartlett. The Student t-test was used to compare
two normally distributed populations. One-way analyses of variance (ANOVA) with subsequent
post-hoc multiple comparisons using the Tukey–Kramer multiple comparisons test were used for
parametric comparisons. The Kruskal–Wallis test was used for nonparametric multiple comparisons.
To perform post-hoc pairwise comparisons following Kruskal–Wallis test, Dunn’s non-parametric
multiple comparisons procedure was used. Differences with probability values p < 0.05 were considered
statistically significant.
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Figure A1. CXCR4-mRNA expression. (a) Conventional RT-PCR showing the presence of CXCR4 
mRNA in cells before and after transfection (CPCCTRL vs. CPCCXCR4). The exogenous sequence (c-Myc) 
is only present into transfected cells (CPCCXCR4). (b)The hCXCR4-mRNA is slightly present in ExoCTRL 
and its expression increases in Exo produced by transfected cells (ExoCXCR4). The sequence of c-Myc 
Figure A1. CXCR4-mRNA expression. (a) Conventional RT-PCR showing the presence of CXCR4
mRNA in cells before and after transfection (CPCCTRL vs. CXCR4). The exogenous sequence (c-Myc)
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is only present into transfected cells (CPCCXCR4). (b)The hCXCR4-mRNA is slightly present in ExoCTRL
and its expression increases in Exo produced by transfected cells (ExoCXCR4). The sequence of c-Myc
tag is present in ExoCXCR4. (c) Representative PCR analyses on isolated adult CM from ex vivo
experiments; the sequence of c-Myc tag is present in ExoCXCR4. Primers used for individual PCR assays
are indicated by numbers in brackets, as for the top drawing. (d) Representative dot immunoblotting
using 4PD4-PAPP30 mAb that selectively detects dimeric (active) PAPP-A, which was unchanged in
naïve Exo, Exo derived from cell transfected with backbone plasmid (ExoCTRL) and Exo derived from
cells overexpressing hCXCR4 (ExoCXCR4 ). (e) Representative western blotting analysis showing level
of expression in Exo, ExoCTRL and ExoCXCR4.
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Figure A3. In vitro bioactivities of ExoCXCR4. (a) ExoCTRL, and ExoCXCR4 inhibit staurosporine-induced 
death in human iPS-derived CM (b) (n = 5 patients/group for ExoCTRL and ExoCXCR4; n = 4 repeated 
measurements for PBS and FBS) # p < 0.05 (one-way analyses of variance-ANOVA with post-hoc 
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Figure A2. (a) Levels of SDF-1α detected by ELISA in rat heart tissue at 3 and 24 h post MI
(n = 4 rats/group for Sham; n = 5 rats/group for 3h and 24h) # p < 0.05 (one-way analyses of
variance-ANOVA with post-hoc multiple comparisons using the Tukey-Kramer multiple comparisons
test for paired parametric comparisons). (b) WB for SDF-1α on HL-1 cell lysate following
staurosporine treatment.
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Figure A4. In vitro transfer of CXCR4 mRNA and protein into target cells. (a) The c-Myc-mRNA 
sequence is transferred by Exo into target cells in both physiological and stress conditions 
(staurosporine). (b) Immunofluorescence staining showing the presence of c-Myc-tag protein (white 
arrows) into adult CM isolated from heart perfused ex vivo with ExoCXCR4cellmiR39. For the wild-type 
CXCR4, protein cells have been stained with a primary anti-CXCR4 antibody, which recognizes 
human and rat protein. (c) Phosphorylation of ERK1/2 is enhanced in HL-1 CM after treatment with 
ExoCXCR4 (n = 5 patients/group for ExoCTRL and ExoCXCR4; n = 5 repeated measurements for PBS ) # p < 
0.05 (one-way analyses of variance-ANOVA with post-hoc multiple comparisons using the Tukey-
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